Portsmouth, United States
Epredia is a biotechnology and healthcare startup with a mission to enhance precision cancer diagnostics, ultimately improving patient outcomes. Established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific, Epredia offers a wide range of solutions that have redefined the anatomical pathology market. The company's trusted brands, including Shandon, Microm, Menzel Gläser, and Richard-Allan Scientific, have positioned Epredia as a global leader in precision cancer diagnostics.
With a legacy dating back to 1937, Epredia has built a reputation for developing groundbreaking technologies and providing essential products in the fight against cancer. Every second of every hour of every day, over a billion Epredia products are employed by customers worldwide. The company's commitment to improving lives and enabling pathologists through enhanced precision cancer diagnostics has been a driving force behind their success.
Although specific details regarding the headquarters, last investment, and last investment investors are not provided, Epredia's dedication to innovation and patient care is evident. With its impactful slogan, "Improving lives by enhancing precision cancer diagnostics," the company's presence in the biotechnology and healthcare industries is poised to make a lasting difference.
